Press Room

13th Global DDF Summit - Drug Delivery Formulation

Start
Monday, June 27, 2022 - 09:00
End
Wednesday, June 29, 2022 - 17:00
Location: Berlin, Germany
Booth Number: Table 24

On June 27th, don’t miss the Dispersome® session 

Pedro Valente | Hovione

 

Pedro Valente
R&D Director - Oral Drug Product Development, Hovione
speaker - Korbinian Lobmann | Zerion Pharma

 

Korbinian Löbmann
CSO, Zerion Pharma

 

  • Day 1 - June 27th, Small Molecules Stream
  • 12:10 PM - 12:40 PM - Solution Spotlights
  • 'Dispersome® – Novel Bioavailability Enhancement Technology for Poorly Water-Soluble APIs Scalable from Grams to Tons'

The Dispersome® technology is a novel solubility enhancing approach that is based on using the protein beta-lactoglobulin (BLG) as novel pharmaceutical excipient. By mixing a drug compound with this by-product from cheese production, one obtains a unique amorphous composition of small molecule drugs and proteins.

The technology has been shown to dramatically increase the solubility and bioavailability of poorly soluble drugs, which will be demonstrated by selected case studies in this presentation. These co-amorphous drug-BLG formulations can be manufactured by Spray Drying which is a continuous and scalable manufacturing process commonly used in the pharmaceutical industry. A roadmap of the Spray Drying development process will be presented, with all the main steps to bring these new formulations from the laboratory to production scale suitable for Metric Tons.

A focus will be given to the importance of lab-scale familiarization and supporting studies throughout the development process and how computational, statistical tools combined with prior knowledge can be capitalized to reduce risk while maximizing time and resources.

Why you should attend:

  • Learn more about innovation in bioavailability enhancement using BLG
  • Learn how these formulations can be scaled-up to meet commercial supply demand

 

For more information on our session please visit the DDFevent.com

 

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025